questionsmedicales.fr
Composés chimiques organiques
Hydrocarbures
Hydrocarbures cycliques
Hydrocarbures aromatiques
Dérivés du benzène
Phénols
Catéchols
Masoprocol
Masoprocol : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masoprocol : Questions médicales les plus fréquentes",
"headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-01",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masoprocol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Catéchols",
"url": "https://questionsmedicales.fr/mesh/D002396",
"about": {
"@type": "MedicalCondition",
"name": "Catéchols",
"code": {
"@type": "MedicalCode",
"code": "D002396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.657.166"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masoprocol",
"alternateName": "Masoprocol",
"code": {
"@type": "MedicalCode",
"code": "D009637",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammed Baqur S Al-Shuhaib",
"url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib",
"affiliation": {
"@type": "Organization",
"name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Sarfaraz Alam",
"url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam",
"affiliation": {
"@type": "Organization",
"name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland."
}
},
{
"@type": "Person",
"name": "Salman Ali Khan",
"url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."
}
},
{
"@type": "Person",
"name": "Hayder O Hashim",
"url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Daniel H Obayes",
"url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes",
"affiliation": {
"@type": "Organization",
"name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.",
"datePublished": "2022-11-08",
"url": "https://questionsmedicales.fr/article/36348359",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13023-022-02526-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "COSMO models for the pharmaceutical development of parenteral drug formulations.",
"datePublished": "2023-04-27",
"url": "https://questionsmedicales.fr/article/37120066",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejpb.2023.04.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36624086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.accounts.2c00464"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical trial considerations for pediatric cancer drug development.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36749066",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10543406.2023.2172424"
}
},
{
"@type": "ScholarlyArticle",
"name": "Changing incentives to ACCELERATE drug development for paediatric cancer.",
"datePublished": "2023-01-16",
"url": "https://questionsmedicales.fr/article/36645217",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.5627"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénols",
"item": "https://questionsmedicales.fr/mesh/D010636"
},
{
"@type": "ListItem",
"position": 8,
"name": "Catéchols",
"item": "https://questionsmedicales.fr/mesh/D002396"
},
{
"@type": "ListItem",
"position": 9,
"name": "Masoprocol",
"item": "https://questionsmedicales.fr/mesh/D009637"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masoprocol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masoprocol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masoprocol",
"description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masoprocol",
"description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masoprocol",
"description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masoprocol",
"description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masoprocol",
"description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masoprocol",
"description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Drug+Development&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le masoprocol est-il diagnostiqué ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes le masoprocol peut-il traiter ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés."
}
},
{
"@type": "Question",
"name": "Le masoprocol provoque-t-il des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avec le masoprocol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Dans quel type de traitement le masoprocol est-il utilisé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés."
}
},
{
"@type": "Question",
"name": "Comment le masoprocol est-il administré ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement appliqué localement sous forme de crème ou de gel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le masoprocol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du masoprocol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation."
}
}
]
}
]
}
Extremely high prices facilitate drug development for ultra-rare diseases (ultra-orphan drugs). However, various problems arise in terms of healthcare financing and fairness, and the status of ultra-o...
Drug prices tended to increase as the expected number of patients to whom the drug was administered decreased; however, this trend diminished when the expected number of patients was less than 1000. O...
The status of drug prices and expected sales differed beyond a threshold of 1000 expected patients, indicating that recovering the development cost for ultra-orphan drugs is difficult. In addition, th...
The aqueous solubility of active pharmaceutical ingredients is one of the most important features to be considered during the development of parenteral formulations in the pharmaceutical industry. Com...
The outbreak of the coronavirus disease 2019 (COVID-19) pandemic and swift approval of two mRNA vaccines have put nucleic acid therapeutics in the spotlight of both the scientific community and the ge...
Oncology has been one of the most active therapeutic areas in medicinal products development. Despite this fact, few drugs have been approved for use in pediatric cancer patients when compared to the ...
More effective incentives are needed to motivate paediatric oncology drug development, uncoupling it from dependency on adult drug development. Although the current European and North-American legisla...
We propose changes in the timing and nature of the rewards within the European Paediatric Medicine Regulation (PMR) and Regulation on Orphan Medicinal Products (both currently under review), which wou...
We suggest modifying the PMR to ensure mechanism-of-action driven mandatory PIP and reorganization of incentives to a stepwise and incremental approach. Interim and final deliverables should be define...
Additionally, to address the critical gap in the current framework where there is a complete lack of incentives to promote paediatric-specific cancer drug development, we propose the introduction of e...
G-protein-coupled receptors (GPCRs) can form homodimers or heterodimers that modulate specific signal transduction pathways to regulate a wide range of physiological and pathological functions. As suc...
Diabetic retinopathy is one of the withering disorders that has been making the lives of patients miserable. Arising as a result of chronic high blood sugar levels in diabetes patients, retinopathy ha...
While the drug development literature provides numerous estimates of the financial costs to bring a new drug to market, the investment of patient-participants in the research process has not been desc...
Five drugs are now approved or in trials for genetic condition that triggers misplaced bone growth....
Osteoarthritis (OA) is the most common form of arthritis worldwide, affecting ~500 million people, yet there are no effective treatments to halt its progression. Without any structure-modifying agents...